ProfileGDS5678 / 1434041_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 73% 72% 73% 71% 72% 73% 73% 73% 73% 72% 73% 72% 73% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6331573
GSM967853U87-EV human glioblastoma xenograft - Control 24.6173872
GSM967854U87-EV human glioblastoma xenograft - Control 34.6539973
GSM967855U87-EV human glioblastoma xenograft - Control 44.6172771
GSM967856U87-EV human glioblastoma xenograft - Control 54.6087472
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6486673
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6711973
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6327673
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.7727873
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6400872
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6367473
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.6309672
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6399373
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6418873